Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Chandler Robinson Sells 29,056 Shares

Posted by Brenda Bartman on Sep 28th, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) CEO Chandler Robinson sold 29,056 shares of Monopar Therapeutics stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares in the company, valued at $8,735,496. This represents a 22.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

Shares of MNPR stock traded down $1.52 during trading on Monday, hitting $83.72. 268,172 shares of the company were exchanged, compared to its average volume of 134,390. The business’s 50-day simple moving average is $109.77 and its 200 day simple moving average is $82.32. The firm has a market capitalization of $561.76 million, a price-to-earnings ratio of -38.58 and a beta of 1.49. Monopar Therapeutics Inc. has a twelve month low of $50.07 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. On average, equities analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MNPR has been the subject of a number of recent analyst reports. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. HC Wainwright lifted their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Finally, Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Monopar Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $121.36.

View Our Latest Stock Analysis on MNPR

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently modified their holdings of the business. Siren L.L.C. increased its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the period. Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics during the second quarter worth about $7,124,000. Bank of America Corp DE increased its stake in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the period. Finally, Walleye Capital LLC bought a new position in Monopar Therapeutics during the first quarter valued at about $3,458,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.